First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP
Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart’s pumping function, providing peak flows greater than 3.5 L/min.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005398/en/
Impella ECP is the world’s smallest heart pump. (Graphic: Business Wire)
The first Impella ECP patient was treated by Amir Kaki, MD, an interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital in Detroit, part of Ascension Michigan. The patient had severe narrowing of his coronary arteries. Dr. Kaki successfully opened the patient’s arteries by performing several percutaneous interventions with support from Impella ECP including atherectomy and two one-minute long balloon inflations.
The second patient was treated at The Christ Hospital in Cincinnati by Timothy Smith, MD, an interventional cardiologist and director of cardiovascular intensive care unit, cardiogenic shock and ECMO programs. The patient had severe narrowing of the coronary arteries, including complex left main bifurcation disease and low ejection fraction. Percutaneous coronary intervention was successfully performed with support from Impella ECP.
“Ascension St. John Hospital is pleased to be the heart center leading this patient milestone as part of the early feasibility study of the smallest heart pump in the world,” said Dr. Kaki. "This new technology allows for a less invasive approach which may ultimately lead to better healing and recovery.”
“This groundbreaking technology will help more physicians provide critical hemodynamic support to patients who need it,” said Dr. Smith. “In the patient we treated, Impella ECP enabled the procedure by providing hemodynamic stability while we treated complex disease in a patient with low ejection fraction.”
Impella ECP is being studied under a U.S. Food and Drug Administration (FDA) early feasibility study. It is designed to provide temporary circulatory support and left ventricular unloading in patients undergoing a high-risk PCI. Impella ECP is delivered though a slender profile 9Fr sheath. It is un-sheathed in the descending aorta and expands. Then, using a specially designed pigtail, it crosses the aortic valve without a wire, and pumps from inside the left ventricle. When the procedure is complete, the pump is re-sheathed back down to 9Fr and removed.
“Impella ECP is part of Abiomed’s commitment to continually innovate, patent new breakthroughs, and improve patient outcomes by developing smaller, smarter, and more connected technology,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer.
The primary endpoint of the FDA early feasibility study is successful delivery, initiation and maintenance of adequate hemodynamic support and a composite rate of major device-related adverse events during high-risk PCI. The study protocol will enroll and treat up to five U.S. patients who require revascularization. If successful, enrollment will be expanded to additional patients, pending FDA approval.
Impella ECP is an investigational device, limited by federal law to investigational use only.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD Study, STEMI DTU and Automated Impella Controller are pending trademarks of Abiomed, Inc.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005398/en/
Contact information
Sarah Karr
Communications Manager
978-882-8211
skarr@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seven2 and HRK LUNIS Announce Successful Double Closing17.9.2025 11:01:00 EEST | Press release
Seven2, a leading European private equity firm, and HRK LUNIS, one of the leading independent wealth managers in Germany, have successfully completed both the majority stake acquisition of HRK LUNIS by Seven2, announced in March of this year, and the merger with Grossbötzl, Schmitz & Partner, announced in April. The smooth approval process is a positive sign for the German wealth management market and underlines the stability of the sector. With the completed double closing, HRK LUNIS's client assets under management have increased to approximately €7.5 billion and the number of employees to 120. The acquisition of HRK LUNIS is Seven2’s first investment in Germany, marking a key strategic milestone to further expand the private equity firm's position in Europe. Together with Seven2, HRK LUNIS will continue its growth trajectory, further develop its product offering, and optimize its digital capabilities to drive maximum customer benefits. The company offers a broad and competitive rang
Quectel Appoints Natasha Barrios as Senior Vice President of Sales for EMEA Region17.9.2025 11:00:00 EEST | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, is pleased to announce the appointment of Natasha Barrios as Senior Vice President of Sales for the EMEA region. Natasha transitions to the role from her position as Vice President of Sales for North America where she helped to shape Quectel’s North American sales strategy, delivering exponential revenue growth across the region and scaling the team tenfold since 2017. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917625759/en/ Quectel appoints Natasha Barrios as Senior Vice President of Sales for EMEA region As part of her new role in EMEA, Natasha will spearhead the strategy to expand the reach of Quectel’s comprehensive portfolio of IoT products and services and drive continued year-over-year sales growth in EMEA. Her leadership and methodology is grounded in Quectel’s values of dedication, preparation, focus, innovation and mutual success with c
ISN ® Partners with Esso Exploration Angola Limited to Advance Contractor Management17.9.2025 11:00:00 EEST | Press release
ISN, the global leader in contractor and supplier information management services, announced the expansion of ISNetworld to Esso Exploration Angola Limited, an ExxonMobil affiliate, specialized in oil exploration and production. Through this collaboration, ISN will support Esso Angola in streamlining contractor management and oversight, meeting local compliance requirements, and increasing visibility into worker-level training and competency. “ExxonMobil has been a trusted partner of ISN for many years, and we are excited to continue our relationship with the Esso Angola team,” said David Bibby, Vice President of Europe, MEA, and APAC Operations at ISN. “This next step gives ExxonMobil’s team the tools to help standardize operations internationally, and create safer, more efficient job sites around the globe.” Building on a relationship that spans more than two decades with ISN, Esso Angola will leverage tools and services, such as Training Qualification and the Online Training tool, t
ThinkPalm and RAD Join Forces to Deliver a Smart Business IoT Solution, Offering CSPs a Competitive Edge17.9.2025 10:00:00 EEST | Press release
ThinkPalm and RAD have partnered to integrate NetvirE, ThinkPalm’s advanced IIoT platform, and RAD’s Smart Business IoT solution to enable smarter industrial operations. This collaboration gives Communication Service Providers (CSPs) a competitive edge in digital transformation, remote asset management, and IoT services. 360°, End-to-End IoT Offering The Smart Business IoT solution combines advanced IoT gateways, smart sensors, and intelligent dashboards into one integrated system. It delivers real-time, historical, and AI-driven insights for remote monitoring, predictive maintenance, and activity detection, enabling CSPs to move beyond SIM-based plans and offer high-value, integrated solutions for smarter asset decisions without requiring IT expertise. Expanding CSP Horizons in the UK and Europe For CSPs in competitive markets like the UK and Europe, ThinkPalm’s expertise combined with RAD's industry leadership offers an unparalleled advantage. Together, they deliver secure, tailored
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 09:57:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September 17 to 20 in Paris, France. At the congress, Almirall contributes a total of 44 scientific abstracts focused on advancing patient care across the company’s broad portfolio of dermatological treatments including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa. With a strong emphasis on real-world evidence, patient-reported outcomes, and well-being, Almirall’s scientific programme includes multiple presentations, two expert-led symposia on psoriasis and atopic dermatitis, and an interactive exh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom